Should Harley-Davidson’s “Back to the Bricks” Strategy and New Models Shift the Narrative for HOG Investors?
Harley-Davidson, Inc. HOG | 0.00 |
- In early June 2026, Harley-Davidson participated in the Baird Global Consumer, Technology & Services Conference, where CEO Artie Starrs and Investor Relations leadership discussed recent 8% global motorcycle retail sales growth, a new “Back to the Bricks” plan, and upcoming model launches like the 2026 Sprint and the 2027 return of the Sportster.
- These updates, alongside board changes and renewed criticism from anti-DEI activists, highlight how Harley-Davidson’s refreshed strategy and leadership approach are being tested against shifting customer expectations and brand perceptions.
- We’ll now consider how Harley-Davidson’s “Back to the Bricks” strategy outlined at the conference could influence the existing investment narrative.
The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Harley-Davidson Investment Narrative Recap
To own Harley-Davidson today, you need to believe the “Back to the Bricks” plan can convert recent 8% global retail sales growth into healthier earnings despite softer profitability and an inexperienced management team. The key near term catalyst is whether new, more accessible models like the Sprint can broaden the rider base without eroding margins. The latest conference commentary and renewed anti-DEI criticism do not appear to materially change that central risk reward balance in the short term.
The most relevant update here is the “Back to the Bricks” strategy, which ties product launches, dealer health and cost focus directly to Harley-Davidson’s core investment case. With Q1 2026 net income at US$24.77 million and ongoing buybacks reducing the share count, execution on this plan could be important for how investors weigh modest earnings growth forecasts against valuation. How effectively the company aligns brand, pricing and new models will likely frame the next phase of the story.
Yet behind the refreshed branding and new models, investors should still pay close attention to how Harley-Davidson manages mounting criticism around...
Harley-Davidson's narrative projects $3.9 billion revenue and $231.2 million earnings by 2029. This assumes revenue will decline by 3.4% per year and an earnings increase of about $0.8 million from $230.4 million today.
Uncover how Harley-Davidson's forecasts yield a $25.45 fair value, a 4% upside to its current price.
Exploring Other Perspectives
Before this news, the most optimistic analysts still expected revenue to shrink about 6 percent a year and earnings to fall toward roughly US$338 million, so if you are weighing their more upbeat view against concerns about demographic headwinds, it is worth recognizing how widely opinions can differ and that both narratives may need updating as Harley-Davidson’s new strategy and brand debates play out.
Explore 4 other fair value estimates on Harley-Davidson - why the stock might be worth as much as 31% more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Harley-Davidson research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Harley-Davidson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harley-Davidson's overall financial health at a glance.
Curious About Other Options?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
